Takeda Pharmaceutical Company Limited – Filings and Transcripts

NYSE: TAK
Share price (8/19/26): $18.34
Market cap (8/19/26): $58.0 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 03/31/26 FY 2026

ended 03/31/25 FY 2025

ended 03/31/24 FY 2024

ended 03/31/23 FY 2023

ended 03/31/22 FY 2022

Prospectuses and Registrations Filter

Prospectus for primary offering

Free writing prospectus

Prospectus supplement for primary offering

Automatic shelf registration

Prospectus for primary offering

Ownership Filter

Plump Andrew Stewart

Greenway Nicola Deidre Petal

Greenway Nicola Deidre Petal

Farajallah Awny Samaan Botros

Ibrahim Ramy Riad Ahmed

News Filter

U.S. FDA Approves Takeda’s ORZEYFUL™ (Oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

Financial Appendix

Material disclosure

Completed Issuance of New Shares and Disposal of Treasury Shares Under the Long-Term Incentive Plan for Company Group Employees Outside of Japan With Partial Forfeiture of Rights Granted to Allottees

Articles of Incorporation of Takeda Pharmaceutical Company Limited

Proxies Filter

Annual report of proxy voting record

Other Filter

Notice required by Iran Threat Reduction and Syria Human Rights Act of 2012

Conflict Minerals disclosure

Conflict Minerals disclosure

Conflict Minerals disclosure

Conflict Minerals disclosure